-
Mashup Score: 10
PURPOSE Recent evidence has shown that higher tumor mutational burden strongly correlates with an increased risk of immune-related adverse events (irAEs). By using an integrated multiomics approach, we further studied the association between relevant tumor immune microenvironment (TIME) features and irAEs. METHODS Leveraging the US Food and Drug Administration Adverse Event Reporting System, we extracted cases of suspected irAEs to calculate the reporting odds ratios (RORs) of irAEs for cancers treated with immune checkpoint inhibitors (ICIs). TIME features for 32 cancer types were calculated on the basis of the cancer genomic atlas cohorts and indirectly correlated with each cancer’s ROR for irAEs. A separate ICI-treated cohort of non–small-cell lung cancer (NSCLC) was used to evaluate the correlation between tissue-based immune markers (CD8+, PD-1/L1+, FOXP3+, tumor-infiltrating lymphocytes [TILs]) and irAE occurrence. RESULTS The analysis of 32 cancers and 33 TIME features demonstra
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Medical Oncology Team | OSUCCC – James - 3 month(s) ago
Ohio State’s Division of Medical Oncology has top physicians and researchers working towards a cancer-free world.
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Advances in Cancer Immunotherapy: A Focus on Breast Cancers - 3 month(s) ago
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for breast cancer.
Source: www.sitcancer.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 17
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19 outcomes in patients with breast cancer.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Despite great advances in breast cancer outcomes during the last decade, the benefit of immune checkpoint inhibitors (ICIs) remains limited to a select population of patients with triple-negative breast cancer (TNBC). Monotherapy ICIs have a limited role in breast cancer, with only tissue-agnostic…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19 outcomes in patients with breast cancer.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 197Sexism in academia is bad for science and a waste of public funding - Nature Reviews Materials - 5 month(s) ago
Higher education and research institutions are critical to the well-being and success of societies, meaning their financial support is strongly in the public interest. At the same time, value-for-money principles demand that such investment delivers. Unfortunately, these principles are currently violated by one of the biggest sources of public funding inefficiency: sexism.
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 10Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients - Supportive Care in Cancer - 6 month(s) ago
Purpose Dermatologic adverse events commonly result in the interruption of oncologic treatment, and targeted therapies are the most frequently interrupted class of anticancer agents. Alopecia is a common cutaneous adverse event reported with CK4/6i therapy. Though the clinical characteristics and therapeutic response of EIA have been well documented, few studies have characterized alopecia in…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19 outcomes in patients with breast cancer.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19 outcomes in patients with breast cancer.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors | JCO Precision Oncology https://t.co/B7csCl6IoX